Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Professor Torsten Nielsen completed the MD/PhD program at McGill followed by a residency in Anatomical Pathology at UBC, before taking up a position as a clinician-scientist. He combines work as a musculoskeletal subspecialty pathologist with active grant-funded research programs in breast cancer and sarcomas, the common themes of which are the translation of genomic discoveries into clinically-practical new diagnostics and treatments. Among his accomplishments in sarcoma research are the development of novel diagnostic tests for synovial sarcoma, gastrointestinal stromal tumor and liposarcomas, and the identification of driver events leading to new treatments for tenosynovial giant cell tumor and epithelioid sarcoma. In breast cancer Dr.
Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatment
DNA demethylating agents suppress preclinical models of synovial sarcoma
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97
Synovial Sarcoma Chromatin Dynamics Reveal a Continuum in SS18:SSX Reprograming
Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study
Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102
A clinical calculator to predict disease outcomes in women with triple-negative breast cancer
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
The epigenomics of sarcoma
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma
The prognostic effects of somatic mutations in ER-positive breast cancer
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
The driver landscape of sporadic chordoma
HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)
Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Dual loss of the <scp>SWI</scp>/<scp>SNF</scp> complex <scp>ATPases SMARCA4</scp>/<scp>BRG1</scp> and <scp>SMARCA2</scp>/<scp>BRM</scp> is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type
Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein